

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

| | |
|--------------------|------------|
| Application Number | 09/817,725 |
|--------------------|------------|

| | |
|-------------|----------------|
| Filing Date | March 26, 2001 |
|-------------|----------------|

| | |
|----------------------|-------------------------|
| First Named Inventor | Olaf B. Kinstler et al. |
|----------------------|-------------------------|

| | |
|----------|------|
| Art Unit | 1648 |
|----------|------|

| | |
|---------------|------------------|
| Examiner Name | Not Yet Assigned |
|---------------|------------------|

| | |
|------------------------|--------------|
| Attorney Docket Number | 11009/35975C |
|------------------------|--------------|

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No.¹ | Document Number | Publication Date | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|-----------------------|--------------|---------------------------------|------------------|--|--|
| | | Number-Kind Code² (if known) | MM-DD-YYYY | | |
| ① | A30 | 6,027,720 | 02-22-2000 | Kuga et al. | |
| | | | | | |
| | | | | | |
| | | | | | |

**Examiner
Signature**

Date _____

Date Considered

H-17-04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

FOREIGN PATENT DOCUMENTS

[illegible]


**Examiner
Signature**

Date _____

Considered

1-17-06

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

**FOURTH INFORMATION
DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)**Complete if Known**

| | |
|------------------------|------------------------|
| Application Number | 09/817,725 |
| Filing Date | March 26, 2001 |
| First Named Inventor | Kinstler <i>et al.</i> |
| Art Unit | 1654 |
| Examiner Name | Billy Dell Chism |
| Attorney Docket Number | 11009/35975C |

| | | | |
|-------|---|----|---|
| Sheet | 1 | of | 4 |
|-------|---|----|---|

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| | | Number-Kind Code ² (if known) | | | |
| C | A31 | 3,772,264 | 11-13-1973 | Bayer <i>et al.</i> | |
| | A32 | 5,109,120 | 04-28-1992 | Ueno and Fujino | |
| | A33 | 5,324,844 | 06-28-1994 | Zalipsky | |
| | A34 | 5,589,356 | 12-31-1996 | Tam | |
| | A35 | 5,597,797 | 01-28-1997 | Clark | |
| | A36 | 5,612,460 | 03-18-1997 | Zalipsky | |
| | A37 | 5,646,113 | 07-08-1997 | Attie <i>et al.</i> | |
| | A38 | 5,661,122 | 08-26-1997 | Clark <i>et al.</i> | |
| | A39 | 5,747,646 | 05-05-1998 | Hakimi <i>et al.</i> | |
| | A40 | 5,935,924 | 10-10-1999 | Bunting <i>et al.</i> | |
| | A41 | 6,673,347 | 01-06-2004 | Offord <i>et al.</i> | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ² |
|-----------------------|--------------------------|---|-----------------------------------|--|---|----------------|
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| C | B31 | JP-62-115280 (equivalent of B20) | 05-26-1987 | Takeda Chemical Industries Ltd. | | |
| | B32 | JP-62-129298 (English language translation included) | 06-11-1987 | Chugai Pharmaceutical Co. Ltd. | | |
| | B33 | JP-62-236488 (English language translation included) | 10-16-1987 | Chugai Pharmaceutical Co. Ltd. | | |
| | B34 | JP-62-236497 (English language translation included) | 10-16-1987 | Chugai Pharmaceutical Co. Ltd. | | |
| | B35 | JP-62-289522 (equivalent of B23) | 12-16-1987 | Cetus Corp. | | |
| | B36 | JP-62-503171 (equivalent of B49) | 12-17-1987 | Cetus Corp. | | |
| | B37 | JP-63-10800 (equivalent of A32) | 01-18-1988 | Takeda Chemical Industries Ltd. | | |
| | B38 | JP-63-126900 (English language translation included) | 05-30-1988 | Takeda Chemical Industries Ltd. | | |
| | B39 | JP-63-500636 (English language translation included) | 03-10-1988 | Kirin Amgen Inc. (US) | | |
| | B40 | JP-63-60938 (English language translation included) | 03-17-1988 | Meiji Milk Prod. Co. Ltd. | | |
| | | | | | | |
| C | B48 | DE 29 30 542 (English language translation included) | 02-12-1981 | Hoechst AG. | | |
| | B49 | EP 229 108 | 07-22-1987 | Cetus Corp. | | |
| | B50 | EP 402 378B | 12-19-1990 | Cetus Oncology Corp. | | |
| | B51 | EP 426 488 B | 05-08-1991 | Nihon Chemical Research Kabushiki Kaisha also known as JCR Pharmaceuticals Co., Ltd. | | |
| | B52 | EP 510 356A | 10-28-1992 | F. Hoffmann-La Roche AG | | |
| | B53 | EP 567 566 A | 11-03-1993 | Amgen Inc. | | |
| | | | | | | |

| | | | |
|-----------------------|--|--------------------|---------|
| Examiner Signature | | Date Considered | 1-17-06 |
|-----------------------|--|--------------------|---------|

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|------------------------|
| Substitute for form 1449A/B/PTO FOURTH INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 09/817,725 |
| | | | | Filing Date | March 26, 2001 |
| | | | | First Named Inventor | Kinstler <i>et al.</i> |
| | | | | Art Unit | 1654 |
| | | | | Examiner Name | Billy Dell Chism |
| Sheet | 2 | of | 4 | Attorney Docket Number | 11009/35975C |

| | | | | | | |
|--|-----|---|------------|--|--|--|
| | B54 | JP-5-170796 (English language translation included) | 07-09-1993 | Sumitomo Pharmaceuticals Company Limited | | |
| | B55 | WO 87/00056 (PCT) | 01-15-1987 | Cetus Corp. | | |
| | B56 | WO 90/05534 (PCT) | 05-31-1990 | Genentech, Inc. | | |
| | B57 | WO 92/16221 (PCT) | 10-01-1992 | Synergen, Inc. | | |
| | B58 | WO 93/00109 (PCT) | 01-07-1993 | Genentech, Inc. | | |
| | B59 | WO 94/12219 (PCT) | 06-04-1994 | Synergen, Inc. | | |
| | B60 | WO 95/00846 (PCT) | 01-05-1995 | TAM, James P. | | |
| | B61 | WO 95/32003 (PCT) | 11-30-1995 | Amgen Boulder Inc. | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.


| NON PATENT LITERATURE DOCUMENTS | | | | | | |
|---------------------------------|-----------------------|---|--|--|--|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | | T ² |
| | C24 | CRC Standard Mathematical Tables, 26 th ed., (Beyer, W.H., Ed.) CRC Press, Inc. Boca Raton, FL, 1981, p. 125 | | | | |
| | C26 | FILGRASTIM Clinical Practice, Morstyn, G. and T.M. Dexter, Eds., Marcel Dekker Inc., New York, NY (1993), p.351 | | | | |
| | C55 | ACHARYA <i>et al.</i> , <i>J. Biol. Chem.</i> , "Schiff Base Adducts of Glyceraldehyde with Hemoglobin", 258(4): 2296-2302 (1983) | | | | |
| | C56 | ACHARYA <i>et al.</i> , <i>J. Biol. Chem.</i> , "Reductive Hydroxyethylation of Hemoglobin A", 258(22): 13761-13767 (1983) | | | | |
| | C57 | ACHARYA <i>et al.</i> , <i>J. Biol. Chem.</i> , "Selectively in the Modification of the α -Amino Groups of Hemoglobin on Reductive Alkylation with Aliphatic Carbonyl Compounds", 260(10): 6039-6046 (1985) | | | | |
| | C58 | BENHAR <i>et al.</i> , <i>J. Biol. Chem.</i> , "Pseudomonas Exotoxin A Mutants: Replacement of Surface-Exposed Residues in Domain III with Cysteine Residues that can be Modified with Polyethylene Glycol in a Site-Specific Manner", 269(18):13398-13404 (1984) Issue of May 6 Received 8/26/93 | | | | |
| | C59 | BERGER and PIZZO, <i>Blood</i> , "Preparation of Polyethylene Glycol-Tissue Plasminogen Activator Adducts that Retain Functional Activity: Characteristics and Behavior in Three Animal Species", 71(6)(June):1641-1647 (1988) | | | | |
| | C60 | BRYGIER <i>et al.</i> , <i>Applied Biochemistry and Biotechnology</i> , "Covalent Attachment of Poly(ethyleneglycol) of Peptides and Proteins", 42:127-135 (1993) | | | | |
| | C61 | CUNICO <i>et al.</i> , <i>J. Chromatography</i> , "Characterization of polyethylene glycol modified proteins using charge-reversed capillary electrophoresis", 559:467-477 (1991) | | | | |
| | C62 | DAS <i>et al.</i> , <i>J. Amer. Chem. Soc.</i> , "New model visual pigments. Spectroscopy of Poly(ethylene glycol) Peptide Schiff Bases of Retinal", 101(1):239-240 (1979) | | | | |
| | C63 | DELGADO <i>et al.</i> , <i>J. Biochem. Biophys. Methods</i> , "Quantitative analysis of polyethylene glycol (PEG) in PEG-modified proteins/cytokines by aqueous two-phase systems", 29:237-250 (1994) | | | | |
| | C64 | DIDONATO <i>et al.</i> , <i>J. Biol. Chem.</i> , "Selective Carboxymethylation of the α -Amino Groups of Hemoglobin", 258(19): 11890-11895 (1983) | | | | |

| | | | |
|--------------------|---|-----------------|---------|
| Examiner Signature |  | Date Considered | 1-18-06 |
|--------------------|---|-----------------|---------|

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|------------------------|
| Substitute for form 1449A/B/PTO | | | | Complete if Known | |
| FOURTH INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Application Number | 09/817,725 |
| | | | | Filing Date | March 26, 2001 |
| | | | | First Named Inventor | Kinstler <i>et al.</i> |
| | | | | Art Unit | 1654 |
| | | | | Examiner Name | Billy Dell Chism |
| Sheet | 3 | of | 4 | Attorney Docket Number | 11009/35975C |

| | | |
|-----|--|--|
| C65 | EHRAT and LUISI, <i>Biopolymers</i> , "Synthesis and Spectroscopic Characterization of Insulin Derivatives Containing One or Two Poly(ethylene oxide) Chains at Specific Positions", 22:569-573 (1983) | |
| C66 | FRANCIS <i>et al.</i> , <i>Biomedicine and Pharmacotherapy</i> , "PEG-Cytokines: Improved Pharmaceutical Properties and Dissociation of Individual Bioactivities", 46(5-7):305 (Abstract 133) (1992) | |
| C67 | HARRIS and WISER, American Chemical Society, "Characterization of products formed from reaction of polyethylene glycol acetaldehyde with various bases", 201st National Meeting, Atlanta, GA, April 14-19, 1991, Abstracts Part 2, Abstract 78 | |
| C68 | JACKSON <i>et al.</i> , <i>Anal. Biochem.</i> , "Synthesis, Isolation, and Characterization of Conjugates of Ovalbumin with Monomethoxypolyethylene Glycol Using Cyanuric Chloride as the Coupling Agent", 165:114-127 (1987) | |
| C69 | JENTOFT and DEARBORN, <i>Methods in Enzymology</i> , "Protein Labeling by Reductive Alkylation", 91:570-579 (1983) | |
| C70 | JIANG and DALTON, <i>Biochimica et Biophysica Acta</i> , "Chemical modification of the hydroxylase of soluble methane monooxygenase gives one form of the protein with significantly increased thermostability and another that functions well in organic solvents", 1201:76-84 (1994) | |
| C71 | KATRE <i>et al.</i> , <i>Proc. Nat'l. Acad. Sci. USA</i> , "Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model", 84:1487-1491 (1987) | |
| C72 | KATRE, <i>J. Immunol.</i> , "Immunogenicity of Recombinant IL-2 Modified by Covalent Attachment of Polyethylene Glycol", 144(1):209-213 (1990) | |
| C73 | KITA <i>et al.</i> , <i>Drug Design and Delivery</i> , "Characterization of a Polyethylene Glycol Conjugate of Recombinant Human Interferon- γ ", 6:157-167 (1990) | |
| C74 | KOIDE and KOBAYASHI, <i>Biochem. and Biophys. Res. Commun.</i> , "Modification of Amino Groups in Porcine Pancreatic Elastase with Polyethylene Glycol in Relation to Binding Ability Towards Anti-Serum and to Enzymic Activity", 111(2):659-667 (1983) | |
| C75 | KNAUF <i>et al.</i> , <i>J. Biol. Chem.</i> , "Relationship of Effective Molecular Size to Systemic Clearance in Rats of Recombinant Interleukin-2 Chemically Modified with Water-soluble Polymers", 263(29):15064-15070 (1988) | |
| C76 | KNÜSLI <i>et al.</i> , <i>Br. J. Haematol.</i> , "Polyethylene glycol (PEG) modification of granulocyte-macrophage colony stimulating factor (GM-CSF) enhances neutrophil priming activity but not colony stimulating activity", 82:654-663 (1992) | |
| C77 | KROPACHEV <i>et al.</i> , translated from <i>Molekulyarnaya Biologiya</i> , "Certain Properties of Insulin Modified with Synthetic Polymers" 6(5):727-736 (1972) | |
| C78 | KUNITANI <i>et al.</i> , <i>J. Chromatography</i> , "On-line characterization of polyethylene glycol-modified proteins", 588:125-137 (1991) | |
| C79 | KURFÜRST, <i>Anal. Biochem.</i> , "Detection and Molecular Weight Determination of Polyethylene Glycol-Modified Hirudin by Staining after Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis", 200:244-248 (1992) | |
| C80 | LU and FELIX, <i>Peptide Research</i> , "Pegylated Peptides I: Solid-phase Synthesis of N ^α -pegylated Peptides Using Fmoc Strategy", 6(3):140-146 (1993) | |
| C81 | LU and FELIX, <i>Int. J. Peptide Protein Res.</i> , "Pegylated Peptides II: Solid-Phase Synthesis of Amino-, Carboxy- and Side-chain Pegylated Peptides", 43:127-138 (1994) | |
| C82 | MALIK <i>et al.</i> , <i>Exp. Hematol.</i> , "Polyethylene glycol (PEG)-modified granulocyte-macrophage colony-stimulating factor (GM-CSF) with conserved biological activity", 20:1028-1035 (1992) | |
| C83 | NATHAN <i>et al.</i> , <i>Bioconjugate Chem.</i> , "Copolymers of Lysine and Polyethylene Glycol: A New Family of Functionalized Drug Carriers", 4:54-62 (1993) | |
| C84 | NEUBAUER <i>et al.</i> , <i>Diabetes</i> , "Influence of Polyethylene Glycol Insulin on Lipid Tissues of Experimental Animals", 32:953-958 (1983) | |

| | | | |
|--------------------|---|-----------------|---------|
| Examiner Signature |  | Date Considered | 1-19-06 |
|--------------------|---|-----------------|---------|


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---|------------------------|--------------------------|------------------------|
| Substitute for form 1449A/B/PTO | | Complete if Known | |
| FOURTH INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | Application Number | 09/817,725 |
| | | Filing Date | March 26, 2001 |
| | | First Named Inventor | Kinstler <i>et al.</i> |
| | | Art Unit | 1654 |
| | | Examiner Name | Billy Dell Chism |
| Sheet 4 of 4 | Attorney Docket Number | 11009/35975C | |

| | |
|-----|--|
| C85 | NHO <i>et al.</i> , Chpt. 12 in Poly (Ethylene Glycol) Chemistry: Biotechnical and Biomedical Applications, "PEG-Modified Hemoglobin as an Oxygen Carrier", Harris, Ed., Plenum Press, New York (1992) pp. 171-182 |
| C86 | NUCCI <i>et al.</i> , <i>Adv. Drug Delivery Rev.</i> , "The therapeutic value of poly(ethylene glycol)-modified proteins", 6:133-151 (1991) |
| C87 | PEDDER, <i>Seminars in Liver Disease</i> , "Pegylation of Interferon Alfa: Structural and Pharmacokinetic Properties", 23(Suppl. 1):19-22 (2003) |
| C88 | PETTIT <i>et al.</i> , <i>J. Biol. Chem.</i> , "Structure-Function Studies of Interleukin 15 using Site-specific Mutagenesis, Polyethylene Glycol Conjugation, and Homology Modeling", 272(4):2312-2318 (Jan. 24, 1997) |
| C89 | POZNANSKY and JULIANO, <i>Pharmacological Reviews</i> , "Biological Approaches to the Controlled Delivery of Drugs: A Critical Review", 36(4):277-336 (1984) |
| C90 | SMITH <i>et al.</i> , Combined Meeting of British Society for Haematology and British Society for Haemostasis and Thrombosis, "Receptor Binding Studies of Polyethylene Glycol (PEG) Modified Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) with Dissociated Biological Activities", Glasgow, 20-22 March 1991 Blackwell Scientific Publications, 77(Suppl. 1) Abstract V057 |
| C91 | TANAKA <i>et al.</i> , <i>Cancer Res.</i> , "Pharmacokinetics of Recombinant Human Granulocyte Colony-stimulating Factor Conjugated of Polyethylene Glycol in Rats", 51:3710-3714 (July 15, 1991) |
| C92 | TRUITT <i>et al.</i> , <i>Proc. Amer. Assoc. Cancer Res.</i> , "Pharmacodynamic and preliminary pharmacokinetic evaluation of pegylated derivatives of interferon- α 2a", 35:398 (Abstract 2370) (March 1994) |
| C93 | WANG <i>et al.</i> , <i>Cancer Research</i> , "Polyethylene glycol-modified chimeric toxin composed of transforming growth factor α and <i>Pseudomonas</i> Exotoxin", 53:4588-4594 (1993) |
| C94 | WATSON <i>et al.</i> , <i>Biotechniques</i> , "Matrix-Assisted Laser Desorption Mass Spectrometric Analysis of a Pegylated Recombinant Protein", 16(2):278-280 (1994) |
| C95 | YAMASAKI <i>et al.</i> , <i>J. Biochem.</i> , "Modification of Recombinant Human Granulocyte Colony-Stimulating Factor (rhG-CSF) and Its Derivative ND 28 with Polyethylene Glycol", 115:814-819 (1994) |
| C96 | YOSHINAGA <i>et al.</i> , <i>J. Bioactive and Compatible Polymers</i> , "Effects of Polyethylene Glycol Substitution on Enzyme Activity", 2:49-56 (1987) |
| C97 | ZALIPSKY and LEE, Chpt. 21 in Poly (Ethylene Glycol) Chemistry: Biotechnical and Biomedical Applications, "Use of Functionalized Poly(Ethylene Glycol)s for Modification of Polypeptides", Harris, Ed., Plenum Press, New York (1992) |
| C98 | ZIMMERMAN <i>et al.</i> , <i>Cancer Res.</i> , "Schedule Dependency of the Antitumor Activity and Toxicity of Polyethylene Glycol-modified Interleukin 2 in Murine Tumor Models", 49:6521-6528 (December 1, 1989) |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

| | | | |
|--------------------|---|-----------------|---------|
| Examiner Signature |  | Date Considered | 1-20-06 |
|--------------------|---|-----------------|---------|